Payment overview · 2025
General Payments
$739.41
40 reported records · 10 companies
Healthcare provider profile · identity verified
Deelip Chatterjee, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · WEST PATERSON, NJ · NPI 1790894707
Verified facts
What the public records show
CMS Open Payments records show Deelip Chatterjee, M.D. received $739.41 in general payments during 2025 across 40 reported records.
AstraZeneca Pharmaceuticals LP accounted for 38.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $284.42 | 38.5% | 12 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $217.59 | 29.4% | 15 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $68.80 | 9.3% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $38.16 | 5.2% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $37.84 | 5.1% | 2 | 2025 |
| 3B Medical, Inc. | Unresolved — no canonical attribution shown | $23.26 | 3.1% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.39 | 2.5% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $17.76 | 2.4% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $17.39 | 2.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.80 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $739.41 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $166.92 | 4 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $131.87 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $117.50 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $85.72 | 5 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $68.80 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $38.16 | 2 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $37.84 | 2 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $36.08 | 2 | 2025 |
Source payment records
|
|||||
| LUNA Normalized: luna |
Device | 3B Medical, Inc. | $23.26 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $17.39 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $11.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 68 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
68 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
96 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Azithromycin | Azithromycin | 364 | 142 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 310 | 73 |
| Dexamethasone | Dexamethasone | 278 | 126 |
| Omeprazole | Omeprazole | 220 | 39 |
| Metformin Hcl | Metformin Hcl | 214 | 43 |
| Atorvastatin Calcium | Atorvastatin Calcium | 166 | 34 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 161 | 83 |
| Alprazolam | Alprazolam | 155 | 25 |
| Amlodipine Besylate | Amlodipine Besylate | 148 | 34 |
| Clonidine Hcl | Clonidine Hcl | 108 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 31 |
| Torsemide | Torsemide | 105 | 38 |
| Trulicity | Dulaglutide | 96 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 21 |
| Famotidine | Famotidine | 92 | 33 |
| Terazosin Hcl | Terazosin Hcl | 92 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 16 |
| Montelukast Sodium | Montelukast Sodium | 84 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 81 | 35 |
| Levothyroxine Sodium | Levothyroxine Sodium | 79 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 27 |
| Tramadol Hcl | Tramadol Hcl | 71 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 66 | 18 |
| Ozempic | Semaglutide | 65 | 13 |
| Glimepiride | Glimepiride | 62 | 14 |
| Carvedilol | Carvedilol | 61 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | 14 |
| Levofloxacin | Levofloxacin | 59 | 33 |
| Potassium Chloride | Potassium Chloride | 56 | suppressed |
| Eliquis | Apixaban | 51 | 15 |
| Gabapentin | Gabapentin | 49 | 13 |
| Halobetasol Propionate | Halobetasol Propionate | 49 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 49 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 47 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 47 | 20 |
| Linzess | Linaclotide | 47 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 46 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 42 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 42 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 41 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 41 | 18 |
| Losartan Potassium | Losartan Potassium | 41 | suppressed |
| Clonidine | Clonidine | 40 | suppressed |
| Ibuprofen | Ibuprofen | 38 | suppressed |
| Naproxen | Naproxen | 38 | 20 |
| Diazepam | Diazepam | 37 | suppressed |
| Clonazepam | Clonazepam | 34 | suppressed |
| Furosemide | Furosemide | 34 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 33 | suppressed |
| Prednisone | Prednisone | 32 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Meloxicam | Meloxicam | 31 | suppressed |
| Methotrexate | Methotrexate Sodium | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 15 |
| Celecoxib | Celecoxib | 29 | 11 |
| Endocet | Oxycodone Hcl/Acetaminophen | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Lisinopril | Lisinopril | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Allopurinol | Allopurinol | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Metolazone | Metolazone | 25 | suppressed |
| Lactulose | Lactulose | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Xolair | Omalizumab | 24 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 23 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 22 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 22 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Ertapenem | Ertapenem Sodium | 19 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 19 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Temazepam | Temazepam | 18 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 17 | 11 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Minoxidil | Minoxidil | 16 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Proctozone-Hc | Hydrocortisone | 11 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $739.41 · 40 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, Arikayce, BREZTRI, Brinsupri, LUNA, NUCALA, OPSUMIT, PURIFIED CORTROPHIN GEL, TRELEGY ELLIPTA, Tymlos, WAKIX, YUPELRI, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error